Relationship between the preoperative alanine aminotransferase/aspartate aminotransferase ratio and the prognosis of gastrointestinal tumors

doi:10.3877/cma.j.issn.2095-2015.2025.06.017

Abstract

Abstract:

Objective

To investigate the prognostic value of the preoperative alanine aminotransferase to aspartate aminotransferase ratio (LSR) in gastrointestinal tumors.

Methods

A literature search was conducted in the China National Knowledge Infrastructure (CNKI), Wanfang, VIP, PubMed, Embase, and Web of Science databases from January 1, 2015 to January 1, 2025. Studies were screened, data analyzed, and literature quality evaluated according to inclusion and exclusion criteria. The hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to assess the significance of LSR in gastrointestinal tumors.

Results

Nine studies were ultimately selected, all of which were evaluated as having high quality according to the Newcastle-Ottawa Scale. Meta-analysis results showed that LSR was not associated with overall survival in gastric cancer (HR=1.20, 95% CI: 0.88-1.63, P>0.05). However, subgroup analysis showed that LSR>1 was associated with significantly shorter overall survival in gastric cancer patients (HR=1.27, 95% CI: 1.05-1.53, P=0.01). LSR was positively correlated with overall survival in liver cancer patients (HR=0.57, 95% CI: 0.52-0.62, P<0.000 01), and there was no statistically significant association between LSR and overall survival in colorectal cancer patients (HR=1.03, 95% CI: 0.32-3.38, P>0.05), but heterogeneity was high in all cases.

Conclusion

LSR was significantly associated with overall survival in patients with liver cancer and gastric cancer and may serve as a potential indicator for assessing the prognosis of gastrointestinal tumors.

Key words: Digestive tumors, Alanine aminotransferase/aspartate aminotransferase ratio, Prognosis

Yanjing Liu, Xiangjun Xie, Zhi Wei. Relationship between the preoperative alanine aminotransferase/aspartate aminotransferase ratio and the prognosis of gastrointestinal tumors[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(06): 655-660.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.06.017

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I06/655

Figures/Tables 5

References 31

[1]	Majhi S, Baral N, Lamsal M, et al. De Ritis ratio as diagnostic marker of alcoholic liver disease[J]. Nepal Med Coll J, 2006, 8(1): 40-42.
[2]	Ishihara H, Kondo T, Yoshida K, et al. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study[J]. Clin Genitourin Cancer, 2017, 15(5): 598-604.
[3]	Liu X, Meng QH, Ye Y, et al. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer[J]. Carcinogenesis, 2015, 36(2): 243-248.
[4]	Takenaka Y, Takemoto N, Yasui T, et al. Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer[J]. PLoS One, 2016, 11(10): e0164057.
[5]	Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma[J]. Cancer Sci, 2021, 112(6): 2426-2435.
[6]	Zhou J, He Z, Ma S, et al. AST/ ALT ratio as a significant predictor of the incidence risk of prostate cancer[J]. Cancer Med, 2020, 9(15): 5672-5677.
[7]	Knittelfelder O, Delago D, Jakse G, et al. The AST/ALT(De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer[J]. Diagnostics(Basel), 2020, 10(11): 973.
[8]	董雯, 边冬梅, 田晓娟, 等. 结肠癌远期预后的影响因素分析及Nomogram预测模型的建立[J]. 结直肠肛门外科, 2021, 27(4): 356-359.
[9]	韩帮岭, 汪亦民, 薛英威. 术前血清丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值对胃癌患者预后的影响[J]. 中华胃肠外科杂志, 2020, 23(1): 65-70.
[10]	赵杰, 余海波, 朱运海, 等. 肝癌根治术前GGT、ALT/AST和术后临床病理特征与预后的关系[J]. 中华普通外科杂志, 2019, 34(4): 328-331.
[11]	Chen SL, Li JP, Li LF, et al. Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase(ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma[J]. Int J Mol Sci, 2016, 17(6): 911.
[12]	杨新萍, 廖桀. 血清ALT/AST比值(LSR)与胃癌预后的关系[J]. 临床医学研究与实践, 2018, 3(16): 7-9.
[13]	吴佳, 李钟声, 姚寒晖. 胃癌患者术前血清丙氨酸氨基转移酶及天冬氨酸氨基转移酶比值与其预后的关联[J]. 中华全科医学, 2020, 18(11): 1854-1856, 1932.
[14]	陈磊, 张理想, 周超军, 等. 原发性肝细胞癌根治术前GGT值、LSR值与其预后的关系[J]. 肝胆胰外科杂志, 2018, 30(6): 448-452.
[15]	辛建, 张巍. 术前血清丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值和肝癌患者预后的关系[J]. 现代肿瘤医学, 2021, 29(24): 4357-4362.
[16]	李晓冬. 术前血清转氨酶比值联合血清肿瘤标志物对Ⅲ期结直肠癌患者预后的评估价值[D]. 南昌: 南昌大学, 2022.
[17]	Germoush MO, Othman SI, AI-Qaraawi MA, et al. Umbelliferone prevents oxidative stress, inflammation and hematological alterations, and modulates glutamate-nitric oxide-cGMP signaling in hyperammonemic rats[J]. Biomed Pharmacother, 2018, 102: 392-402.
[18]	Chrisikos TT, Zhou Y, Slone N, et al. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer[J]. Mol Immunol, 2019, 110: 24-39.
[19]	Sudo K, Yamada Y, Saito K, et al. TNF-alpha and IL-6 signals from the bone marrow derived cells are necessary for normal murine liver regeneration[J]. Biochim Biophys Acta, 2008, 1782(11): 671-679.
[20]	陈港心, 杜嘉原, 汪富涛, 等. 胃癌根治术治疗患者血清ALB、AFP水平及LSR在预后评估中的价值[J]. 检验医学与临床, 2021, 18(24): 3571-3574, 3579.
[21]	Kunutsor SK, Apekey TA, Van Hemelrijck M, et al. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis[J]. Int J Cancer, 2015, 136(5): 1162-1170.
[22]	赵贺, 王冲, 张文静, 等. 术前LSR、NLR及PLR检测评估结直肠癌预后的应用价值[J]. 分子诊断与治疗杂志, 2022, 14(2): 228-231, 236.
[23]	鲜胜, 付蓉. GGT、GGT/CHE、GGT/ALTA在肝癌诊断中的价值分析[J]. 中国医药导刊, 2013, 15(11): 1894-1895.
[24]	Yen CJ, Kim TY, Feng YH, et al. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma[J]. Liver Cancer, 2018, 7(2): 165-178.
[25]	Huang H, Wang XP, Li XH, et al. Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma[J]. BMC Cancer, 2017, 17(1): 544.
[26]	Tian D, Jiang KY, Huang H, et al. Clinical nomogram for lymph node metastasis in pathological T1 esophageal squamous cell carcinoma: a multicenter retrospective study[J]. Ann Transl Med, 2020, 8(6): 292.
[27]	向文采, 黄修仿, 叶超, 等. 老年胃肠道间质瘤肝转移患者术前血清ALT与AST比值与预后的相关性研究[J]. 现代检验医学杂志, 2022, 37(2): 190-194, 204.
[28]	徐洁, 卢娅萍. 血清内ALT、LSR及NLR对胃肠间质瘤患者病情分级及临床预后的影响[J]. 中国现代医生, 2022, 60(4): 47-51.
[29]	黄俊, 沈才淋, 周克松, 等. 超声造影结合血清ALT与AST比值对胃肠道间质瘤与结直肠癌肝转移的鉴别诊断价值[J]. 现代生物医学进展, 2024, 24(2): 319-323.
[30]	崔成昊, 王砚伟, 洪陈彦, 等. 接受根治性PD的胰腺导管腺癌患者生存预测列线图模型的构建与评估[J]. 中华肝胆外科杂志, 2022, 28(5): 362-367.
[31]	Weatherby D, DiLuglio BE. Blood Chemistry and CBC Analysis: Clinical Laboratory Testing from a Functional Perspective[M]. Jacksonville: Weatherby & Associates, 2012.

第一作者	发表年份	肿瘤类型	样本量(例)	年龄(岁)	肿瘤分期(Ⅰ/Ⅱ/Ⅲ/Ⅳ或Ⅰ+Ⅱ/Ⅲ+Ⅳ,例)	截断值	截断方法	预后指标	NOS评分
Chen^[11]	2016	胃癌	231	23~79	29/52/94/56	0.80	中位数	OS	7
杨新萍^[12]	2018	胃癌	80	-	27/53	0.75	中位数	OS	6
韩帮岭^[9]	2020	胃癌	891	-	53/152/432/45	1.43	ROC	OS	8
吴佳^[13]	2020	胃癌	106	-	5/37/44/20	1.48	ROC	OS	7
陈磊^[14]	2018	肝癌	179	25~82	67/8	1.19	ROC	OS	7
赵杰^[10]	2019	肝癌	187	25~82	69/8	1.19	ROC	OS	7
辛建^[15]	2021	肝癌	100	39~74	63/37	0.903	ROC	OS/PFS	8
李晓冬^[16]	2022	结肠癌	209	-	0/0/209/0	0.667	中位数	OS/PFS	7
董雯^[8]	2021	结肠癌	122	18~70	47/24/41/10	1.210	ROC	OS	8

第一作者	发表年份	肿瘤类型	样本量(例)	年龄(岁)	肿瘤分期(Ⅰ/Ⅱ/Ⅲ/Ⅳ或Ⅰ+Ⅱ/Ⅲ+Ⅳ,例)	截断值	截断方法	预后指标	NOS评分
Chen^[11]	2016	胃癌	231	23~79	29/52/94/56	0.80	中位数	OS	7
杨新萍^[12]	2018	胃癌	80	-	27/53	0.75	中位数	OS	6
韩帮岭^[9]	2020	胃癌	891	-	53/152/432/45	1.43	ROC	OS	8
吴佳^[13]	2020	胃癌	106	-	5/37/44/20	1.48	ROC	OS	7
陈磊^[14]	2018	肝癌	179	25~82	67/8	1.19	ROC	OS	7
赵杰^[10]	2019	肝癌	187	25~82	69/8	1.19	ROC	OS	7
辛建^[15]	2021	肝癌	100	39~74	63/37	0.903	ROC	OS/PFS	8
李晓冬^[16]	2022	结肠癌	209	-	0/0/209/0	0.667	中位数	OS/PFS	7
董雯^[8]	2021	结肠癌	122	18~70	47/24/41/10	1.210	ROC	OS	8

Please choose a citation manager

Content to export